Diabetes induces rapid suppression of adaptive immunity followed by homeostatic T-cell proliferation

Scandinavian Journal of Immunology

Volumn 65, Issue 1, 2007, Pages 22-31

  Luo, B ^b   Chan, W F N ^a   Lord, S J ^a   Nanji, S A ^a   Rajotte, R V ^a   Shapiro, A M J ^a   Anderson, C C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOZOCIN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIABETES MELLITUS; DISEASE ASSOCIATION; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE;

ANIMALS; CORTICOSTERONE; DIABETES MELLITUS, EXPERIMENTAL; HOMEOSTASIS; IMMUNE TOLERANCE; INSULINOMA; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, INBRED NOD; STREPTOZOCIN; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33845693826     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.01863.x     Document Type: Article

References (58)

1. Shapiro AM, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-8.
2. Cattan P, Rottembourg D, Cottet S et al. Destruction of conditional insulinoma cell lines in NOD mice: a role for autoimmunity. Diabetologia 2003;46:504-10.
3. Pericin M, Althage A, Freigang S et al. Allogeneic beta-islet cells correct diabetes and resist immune rejection. Proc Natl Acad Sci USA 2002;99:8203-6.
4. Takayama Y, Ichikawa T, Maki T. Effect of STZ administration on islet isograft and allograft survival in NOD mice. Diabetes 1993;42:324-9.
5. Koulmanda M, Qipo A, Auchincloss H Jr., Smith RN. Effects of streptozotocin on autoimmune diabetes in NOD mice. Clin Exp Immunol 2003;134:210-6.
6. Gaulton GN, Schwartz JL, Eardley DD. Assessment of the diabetogenic drugs alloxan and streptozotocin as models for the study of immune defects in diabetic mice. Diabetologia 1985;28:769-75.
7. Nichols WK, Spellman JB, Vann LL, Daynes RA. Immune responses of diabetic animals. Direct immunosuppressant effects of streptozotocin in mice. Diabetologia 1979;16:51-7.
8. Saiki O, Negoro S, Tsuyuguchi I, Yamamura Y. Depressed immunological defence mechanisms in mice with experimentally induced diabetes. Infect Immun 1980;28:127-31.
9. Handwerger BS, Fernandes G, Riehm T, Yoon JW, Sutherland DE, Brown DM. Alterations in immunological reactivity in encephalomyocarditis virus-induced murine diabetes. I. Defective primary IgM plaque forming cell responses to sheep erythrocytes: correction by islet cell transplantation. Clin Exp Immunol 1985;60:145-50.
10. Moutschen MP, Scheen AJ, Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab 1992;18:187-201.
11. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med 1999;341:1906-12.
12. van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
13. Yoshioka M, Kayo T, Ikeda T, Koizumi A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 1997;46:887-94.
14. Kayo T, Koizumi A. Mapping of murine diabetogenic gene mody on chromosome 7 at D7Mit258 and its involvement in pancreatic islet and beta cell development during the perinatal period. J Clin Invest 1998;101:2112-8.
15. Nanji SA, Hancock WW, Luo B et al. Combined ICOS and CD40L costimulation blockade induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in NOD mice. Diabetes 2006;55:27-33.
16. Efrat S, Fusco-DeMane D, Lemberg H, al Emran O, Wang X. Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene. Proc Natl Acad Sci USA 1995;92:3576-80.
17. Fleischer N, Chen C, Surana M et al. Functional analysis of a conditionally transformed pancreatic beta-cell line. Diabetes 1998;47:1419-25.
18. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991;145:185-92.
19. Korbutt GS, Suarez-Pinzon WL, Power RF, Rajotte RV, Rabinovitch A. Testicular Sertoli cells exert both protective and destructive effects on syngeneic islet grafts in non-obese diabetic mice. Diabetologia 2000;43:474-80.
20. De Nicola AF, Fridman O, Del Castillo EJ, Foglia VG. Abnormal regulation of adrenal function in rats with streptozotocin diabetes. Horm Metab Res 1977;9:469-73.
21. Rhees RW, Wilson CT, Heninger RW. Influence of streptozotocin diabetes and insulin therapy on plasma corticosterone levels in male rats. Horm Metab Res 1983;15:353-4.
22. Serrano MA, Curi R, Parry-Billings M, Williams JF, Newsholme EA. Effects of glucocorticoids on lymphocyte metabolism. Am J Physiol 1993;264:E24-8.
23. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function*. Annu Rev Immunol 2000;18:309-45.
24. Coulombe M, Gill RG. T lymphocyte indifference to extrathymic islet allografts. J Immunol 1996;156:1998-2003.
25. Nicolls MR, Coulombe M, Yang H, Bolwerk A, Gill RG. Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-gamma or IL-4. J Immunol 2000;164:3627-34.
26. Handwerger BS, Fernandes G, Riehm T, Sutherland DE, Brown DM. Alterations in immunological function in streptozotocin-nduced murine diabetes mellitus: correction by islet cell transplantation. Clin Immunol Immunopathol 1984;32:275-84.
27. Hugues S, Mougneau E, Ferlin W et al. Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic beta cells. Immunity 2002;16:169-81.
28. Rayat GR, Rajotte RV, Lyon JG, Dufour JM, Hacquoil BV, Korbutt GS. Immunization with streptozotocin-treated NOD mouse islets inhibits the onset of autoimmune diabetes in NOD mice. J Autoimmun 2003;21:11-5.
29. Kupfer TM, Crawford ML, Pham K, Gill RG. MHC-mismatched islet allografts are vulnerable to autoimmune recognition in vivo. J Immunol 2005;175:2309-16.
30. Goss JA, Nakafusa Y, Finke EH, Flye MW, Lacy PE. Induction of tolerance to islet xenografts in a concordant rat-to-mouse model. Diabetes 1994;43:16-23.
31. Li XC, Zand MS, Li Y, Zheng XX, Strom TB. On histocompatibility barriers, Th1 to Th2 immune deviation, and the nature of the allograft responses. J Immunol 1998;161:2241-7.
32. Li XC, Li Y, Dodge I et al. Induction of allograft tolerance in the absence of Fas-mediated apoptosis. J Immunol 1999;163:2500-7.
33. Zheng XX, Markees TG, Hancock WW et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol 1999;162:4983-90.
34. + T cell apoptosis but not immune deviation. Transplantation 2000;69:1176-85.
35. Li XC, Ima A, Li Y, Zheng XX, Malek TR, Strom TB. Blocking the common gamma-chain of cytokine receptors induces T cell apoptosis and long-term islet allograft survival. J Immunol 2000;164:1193-9.
36. Ferrari-Lacraz S, Zheng XX, Kim YS et al. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J Immunol 2001;167:3478-85.
37. Rothstein DM, Livak MF, Kishimoto K et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 2001;166:322-9.
38. Stegall MD, Dean PG, Ninova D et al. alpha4 integrin in islet allograft rejection. Transplantation 2001;71:1549-55.
39. Li H, Inverardi L, Molano RD, Pileggi A, Ricordi C. Nonlethal conditioning for the induction of allogeneic chimerism and tolerance to islet allografts. Transplantation 2003;75:966-70.
40. Nanji SA, Hancock WW, Anderson CC et al. Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am J Transplant 2004;4:526-36.
41. Phillips NE, Markees TG, Mordes JP, Greiner DL, Rossini AA. Blockade of CD40-mediated signaling is sufficient for inducing islet but not skin transplantation tolerance. J Immunol 2003;170:3015-23.
42. Lee MKT, Huang X, Jarrett BP et al. Vulnerability of allografts to rejection by MHC class II-restricted T-cell receptor transgenic mice. Transplantation 2003;75:1415-22.
43. Chandra AP, Salvaris E, Walters SN et al. Fate of alphaGal +/+ pancreatic islet grafts after transplantation into alphaGal knockout mice. Xenotransplantation 2004;11:323-31.
44. Bowen KM, Prowse SJ, Lafferty KJ. Reversal diabetes by islet transplantation: vulnerability of the established allograft. Science 1981;213:1261-2.
45. Stegall MD, Loberman Z, Ostrowska A, Coulombe M, Gill RG. Autoimmune destruction of islet grafts in the NOD mouse is resistant to 15-deoxyspergualin but sensitive to anti-CD4 antibody. J Surg Res 1996;64:156-60.
46. Wu Z, Bensinger SJ, Zhang J et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004;10:87-92.
47. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004;117:265-77.
48. Snow EC, Feldbush TL, Oaks JA. The role of insulin in the response of murine T lymphocytes to mitogenic stimulation in vitro. J Immunol 1980;124:739-44.
49. Otton R, Carvalho CR, Mendonca JR, Curi R. Low proliferation capacity of lymphocytes from alloxan-diabetic rats: involvement of high glucose and tyrosine phosphorylation of Shc and IRS-1. Life Sci 2002;71:2759-71.
50. von Kanel R, Mills PJ, Dimsdale JE. Short-term hyperglycemia induces lymphopenia and lymphocyte subset redistribution. Life Sci 2001;69:255-62.
51. Helderman JH. Role of insulin in the intermediary metabolism of the activated thymic-derived lymphocyte. J Clin Invest 1981;67:1636-42.
52. Buffington CK, El-Shiekh T, Kitabchi AE, Matteri R. Phytohemagglutinin (PHA) activated human T-lymphocytes: concomitant appearance of insulin binding, degradation and insulin-mediated activation of pyruvate dehydrogenase (PDH). Biochem Biophys Res Commun 1986;134:412-9.
53. + T lymphocytes. Metabolism 2004;53:117-22.
54. McInerney MF, Flynn JC, Goldblatt PJ, Najjar SM, Sherwin RS, Janeway CA Jr. High density insulin receptor-positive T lymphocytes from nonobese diabetic mice transfer insulitis and diabetes. J Immunol 1996;157:3716-26.
55. Kitabchi AE, Stentz FB, Umpierrez GE. Diabetic ketoacidosis induces in vivo activation of human T-lymphocytes. Biochem Biophys Res Commun 2004;315:404-7.
56. Kunjara S, Sochor M, Ahmed S, Greenbaum AL, McLean P. Phosphoribosyl pyrophosphate formation in the rat adrenal gland in relation to adrenal growth in experimental diabetes. Diabetes 1992;41:1429-35.
57. Galon J, Franchimont D, Hiroi N et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. Faseb J 2002;16:61-71.
58. Wang J, Charboneau R, Barke RA, Loh HH, Roy S. Mu-opioid receptor mediates chronic restraint stress-induced lymphocyte apoptosis. J Immunol 2002;169:3630-6.